Table 1.
Statistical measure | General explanation | Implication for ANA |
---|---|---|
Sensitivity | Statistical measure of how accurately a test correctly identifies diseased individuals | ANA is used as screening test. High sensitivity is important. The sensitivity for different AARD varies (i.e., higher in systemic lupus erythematosus versus myositis) |
| ||
Specificity | Statistical measure of how well a test correctly identifies absence of the disease in question | Importance of specificity depends on pretest probability. In settings with low pretest probability, high specificity is required. |
| ||
Diagnostic efficiency | Combination of sensitivity and specificity | Not commonly used |
| ||
False negative (clinically) | Negative test result of a diseased individual | ANA is used as screening test. False negative results are undesirable. However, in all AARD, patients without a positive ANA test exist. Therefore, a negative result should never be used to rule out AARD. |
| ||
False positive (clinically) | Positive test result of an individual without the disease in question | In case of low pretest probability, false positive results significantly impact the posttest probability |
| ||
False negative (analytically) | Negative test result in the presence of the respective analyte | See negative positive (clinically) |
| ||
False positive (analytically) | Positive test result in the absence of the respective analyte | See false positive (clinically) |
| ||
Positive predictive value | Ratio of true positive to combined true and false positives. | Depends on the prevalence (pretest probability) |
| ||
Negative predictive value | Ratio of true negatives to combined true and false negatives. | Depends on the prevalence (pretest probability) |
| ||
Positive likelihood ratio | The probability of a positive test results in patients with the disease divided by the probability of a positive test result in individuals without the disease. Independent from prevalence. | #Important information for clinicians. Should be included in the laboratory report together with an explanation of its significance in the context of the test result. |
| ||
Negative likelihood ratio | The probability of a negative test result in patients with the disease divided by the probability of a negative test result in individuals without the disease. Independent from prevalence. | #Important information for clinicians. Should be included in the laboratory report together with an explanation of its significance in the context of the test result. |
#The importance of the likelihood ratio in the laboratory report is controversially discussed, but might improve use of ANA test results in the future.